Design Therapeutics, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDDesign Therapeutics, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 93), indicating clear outperformance against the broad market. Earnings growth of 6% provides fundamental context to the price action. However, price is extended 25% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $13.13 | +10.82% | ABOVE |
| 50 SMA | $11.64 | +25.01% | ABOVE |
| 100 SMA | $10.72 | +35.69% | ABOVE |
| 150 SMA | $9.60 | +51.50% | ABOVE |
| 200 SMA | $8.53 | +70.50% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is DSGN in an uptrend right now?
DSGN has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, DSGN is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is DSGN overbought or oversold?
DSGN's RSI (14) is 56. The stock is in neutral territory, neither overbought nor oversold.
Is DSGN outperforming the market?
DSGN has a Relative Strength (RS) Rating of 93 out of 99. Yes, DSGN is a market leader, outperforming 93% of all stocks over the past 12 months.
Where is DSGN in its 52-week range?
DSGN is trading at $14.55, which is 84% of its 52-week high ($17.25) and 81% above its 52-week low ($3.11).
How volatile is DSGN?
DSGN has a Beta of 1.51 and 52-week volatility of 79%. It's more volatile than the S&P 500 - expect bigger swings.